Evidence map›Paper›PMID 41503676›Full record

ArticleImmunity, inflammation and disease2026

Lipoic Acid Ameliorates Lipopolysaccharide-Induced Inflammation via Inhibition of Glycolysis in RAW264.7 Macrophages.

Liduo Yue, Kai Wang, Rongyuan Wang, Linbei Lu, Lihong Fan

Abstract read
In one paragraph

Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liduo YueShanghai Tenth People's Hospital, Institute of Energy Metabolism and Health, Tongji University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-7184-9170
Kai WangShanghai YangZhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji University, Shanghai, People's Republic of China.
Rongyuan WangSchool of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Linbei LuShanghai Tenth People's Hospital, Institute of Energy Metabolism and Health, Tongji University School of Medicine, Shanghai, China.
Lihong FanShanghai Tenth People's Hospital, Institute of Energy Metabolism and Health, Tongji University School of Medicine, Shanghai, China.ORCID https://orcid.org/0009-0005-9088-8772

Funding

Innovative Flagship Hospital for Integrated Traditional Chinese and Western Medicine ZY(2021-2023)-0205-05)SARS special Grant for traditional Chinese medicine 2023ZYLCY
6 · The paper itself

Abstract

backgroundSustained pulmonary inflammation contributes significantly to lung carcinogenesis. Macrophages play a pivotal role in perpetuating inflammatory responses, undergoing a metabolic shift from oxidative phosphorylation (OXPHOS) to glycolysis upon activation. The interplay between metabolic reprogramming and macrophage polarization remains poorly defined. The objective of this study is to examines the anti-inflammatory mechanism of lipoic acid (LA), focusing on its ability to modulate immunometabolism in activated macrophages.

methodsWe utilized lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages and a murine acute lung injury (ALI) model to evaluate the anti-inflammatory effects of LA. Inflammatory cytokine expression was assessed by qPCR, ELISA, and Western blot. Metabolic profiling was performed using Seahorse XF technology to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), evaluating glycolytic and oxidative metabolic functions.

resultsThis study systematically elucidates the molecular mechanism by which LA modulates macrophage inflammatory responses through targeting the HIF1α/glycolysis axis. The main findings are as follows: (1) In LPS-induced RAW264.7 macrophages, LA treatment significantly inhibited the expression of M1 macrophage markers (iNOS, CD86) and the secretion of proinflammatory cytokines (IL-1β, IL-6, etc.). (2) LA effectively reduced the expression of GSDMD, the key executor of pyroptosis, demonstrating its inhibitory effect on macrophage pyroptosis. (3) Metabolic analysis revealed that LA reversed LPS-induced metabolic reprogramming by decreasing the ECAR and increasing the OCR, thereby suppressing glycolysis. (4) Mechanistic studies showed that siRNA-mediated knockdown of HIF1α replicated both the anti-inflammatory and metabolic regulatory effects of LA, confirming HIF1α as the key target in this pathway. (5) In an ALI mouse model, LA treatment significantly reduced HIF1α expression in lung tissues and effectively alleviated inflammatory responses, further validating the proposed mechanism.

conclusionLA exerts potent anti-inflammatory effects by targeting HIF1α-mediated metabolic reprogramming in macrophages. Our results highlight the therapeutic potential of targeting immunometabolic pathways in inflammatory lung diseases, providing new insights into the mechanism by which LA ameliorates pulmonary inflammation.

Indexed as

Acute Lung InjuryAnti-Inflammatory AgentsGlycolysisInflammationMacrophagesThioctic AcidAnimalsCytokinesHypoxia-Inducible Factor 1, alpha SubunitLipopolysaccharidesMiceRAW 264.7 CellsAnti-Inflammatory AgentsCytokinesHif1a protein, mouseHypoxia-Inducible Factor 1, alpha SubunitLipopolysaccharidesThioctic Acidanti‐inflammationHIF1αlipoic acidmacrophage

Identifiers

PMID41503676
PMCPMC12780877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.